A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

Inclusion Criteria: * Genotypes Hb SS, Hb SC, sickle β°-thalassemia, sickle β+ -thalassemia * Pain consistent with vaso-occlusive crisis (clinical judgment) and not attributable to other causes * Serum CRP ≥5.0 mg/L at time of screening * Fever defined as oral temperature ≥38.0°C at time of screening * Age ≥5 years Exclusion Criteria: * New or suspected new pulmonary infiltrate diagnosed by chest radiography * Females who are nursing, pregnant or intend to become pregnant * Renal dysfunction defined as a creatinine level \>1.2 mg/dL for subjects aged 18 or less or a creatinine level \>1.5 mg/dL for subjects over the age of 18 * Hepatic dysfunction (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\] \>3 × upper limit of normal) * Acute neurologic dysfunction * Any medical condition for which transfusion may be needed imminently, and/or hemoglobin \<5 g/dL * Red blood cell transfusion within 30 days prior to screening * Parenteral or oral corticosteroid therapy (inhaled steroids acceptable) within 7 days prior to screening